Safety and efficacy of pridopidine in patients with Huntingtonʼs disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study - Reilmann, R; McGarry, A; Grachev, I D; European Huntingtonʼs Disease Network; Huntington Study Group investigators (Lancet Neurol, 2019)